Physician profile
David A Scott
NPI 1144267238
$2,412.19
in general payments reported to CMS, 2019-2025
18 companies · $626 in 2025
The $626 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $45.76 · 2021: $111 · 2022: $242 · 2023: $410 · 2024: $849 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836 · Education: $49.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,835.53 |
| Education | $49.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $487.84 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $445.16 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $278.12 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $209.61 | 2020-2025 | Veltassa, Korsuva |
| Amgen INC. | $184.44 | 2022-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $156.44 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $152.20 | 2019-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.02 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $58.68 | 2024-2025 | Ozempic |
| Mallinckrodt Hospital Products INC. | $51.62 | 2024 | Acthar, Terlivaz |
| Lilly USA, LLC | $42.41 | 2023-2024 | Jardiance |
| Cormedix INC. | $39.68 | 2024 | Defencath |
| Glaxosmithkline, LLC. | $38.07 | 2022-2023 | Benlysta |
| Fresenius USA Marketing, INC. | $35.68 | 2021-2024 | Velphoro |
| Horizon Therapeutics Plc | $31.99 | 2023 | Krystexxa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $24.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.88 | 2023 | |
| Alnylam Pharmaceuticals INC. | $18.40 | 2025 | Oxlumo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.